33994-44-4

Basic information

• Product Name: Methyl 3-(4-Iodophenyl)propanoate
• Synonyms: Methyl 3-(4-Iodophenyl)propanoate
• CAS NO: 33994-44-4
• Molecular Formula: C₁₀H₁₁IO₂
• Molecular Weight: 290.09761
• Mol File: 33994-44-4.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Methyl 3-(4-Iodophenyl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-(4-Iodophenyl)propanoate(33994-44-4)
• EPA Substance Registry System: Methyl 3-(4-Iodophenyl)propanoate(33994-44-4)

Safety Data

• Hazardous Substances Data: 33994-44-4(Hazardous Substances Data)

Usage

Description

Methyl 3-(4-Iodophenyl)propanoate is an organic compound that serves as a key intermediate in the synthesis of various chemical compounds and pharmaceuticals. It is characterized by its molecular structure, which includes a methyl ester group and an iodinated phenyl group attached to a propanoate backbone.

Uses

Used in Chemical Synthesis:
Methyl 3-(4-Iodophenyl)propanoate is used as a reactant in the preparation of HKGreen-1, a highly selective fluorescent probe for the detection of peroxynitrite in living cells. This application is significant because peroxynitrite is a reactive nitrogen species involved in various cellular processes and is associated with several diseases, including neurodegenerative disorders and cancer. Methyl 3-(4-Iodophenyl)propanoate's role in synthesizing HKGreen-1 highlights its importance in the development of diagnostic tools for studying peroxynitrite's biological functions and its involvement in disease mechanisms.

Upstream product

• 186581-53-3 diazomethane 
• 1643-29-4 3-(4-iodophenyl)propionic acid 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 60075-78-7 3-(p-iodophenyl)-propanol 
• 889663-66-5 C₃₃H₂₄Cl₂O₇ 
• 213264-51-8 3-(4-iodophenyl)propionaldehyde 
• 213264-53-0 5-hydroxy-7-(4-iodophenyl)-1-(4-methoxy-3-methoxymethoxyphenyl)-heptan-3-one 
• 191996-69-7 C₂₆H₂₆BrNO₄ 
• 134520-64-2 methyl p-(6-hydroxyhexyl)dihydrocinnamate 
• 134520-63-1 methyl p-(6-hydroxy-1-hexynyl)dihydrocinnamate 
• 905966-44-1 5,5-dimethyl-2-[4-(2-(methoxycarbonyl)ethyl)phenyl]-1,3,2-dioxaborinane 
• 103-25-3 3-phenylpropanoic acid methyl ester 
• 490035-82-0 methyl 3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]propionoate 
• 1082059-29-7 methyl 3-(4-((3-ethynylphenyl)ethynyl)phenyl)propanoate 
• 1082059-17-3 methyl 3-(4-((3-aminophenyl)ethynyl)phenyl)propanoate 
• 1082059-12-8 methyl 3-(4-(phenylethynyl)phenyl)propanoate 
• 1082059-14-0 methyl 3-(4-((trimethylsilyl)ethynyl)phenyl)propanoate 

Relevant articles and documents

PROTEIN KINASE C AGONISTS

The present disclosure relates generally to certain diacylglycerol lactone compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by protein kinase C (PKC) agonists, such as HIV.

Novel tail and head group prostamide probes

We report the design and synthesis of novel prostaglandin-ethanolamide (PGE2-EA) analogs containing head and tail group modifications to aid in the characterization of a putative prostamide receptor(s). Our synthetic approach utilizes Horner-Wadsworth-Emmons and Wittig reactions to construct the head and the tail moieties of the key PGE2 precursor, which leads to the final products through a peptide coupling, Swern oxidation and HF/pyridine assisted desilylation. The synthesized analogs were shown not to interact significantly with endocannabinoid proteins and recombinant EP1, EP3 and EP4 receptors and suggest a yet to be identified prostamide receptor as their site(s) of action.

COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is -CR4=CR5.